Two novel MICB alleles with coding polymorphisms in exon 3 were detected by next generation sequencing.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/tan.15581 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Novel and potent MICA/B antibody is therapeutically effective in mutant lung cancer models.
J Immunother Cancer
January 2025
Department of Pathology, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, USA
Background: Concurrent (STK11, KL) mutant non-small cell lung cancers (NSCLC) do not respond well to current immune checkpoint blockade therapies, however targeting major histocompatibility complex class I-related chain A or B (MICA/B), could pose an alternative therapeutic strategy through activation of natural killer (NK) cells.
Methods: Expression of NK cell activating ligands in NSCLC cell line and patient data were analyzed. Cell surface expression of MICA/B in NSCLC cell lines was determined through flow cytometry while ligand shedding in both patient blood and cell lines was determined through ELISA.
Causal relationships between three plasma proteins and non-alcoholic fatty liver disease, mediated by Epstein-Barr virus EA-D antibody levels: a mendelian randomization study.
Sci Rep
October 2024
Department of Hepatobiliary Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, China.
Non-alcoholic fatty liver disease (NAFLD) is a major global health concern, with its prevalence increasing steadily. While plasma proteins have been implicated in NAFLD, establishing causal relationships has been challenging due to confounding factors in observational studies. This study aims to explore the causal relationships between plasma proteins and NAFLD using Mendelian randomization (MR) analysis.
View Article and Find Full Text PDFConcurrent (STK11, KL) mutant Non-Small Cell Lung Cancers (NSCLC) is particularly difficult to treat and does not respond well to current immune checkpoint blockade (ICB) therapies. This is due to numerous mechanisms including low antigen presentation limiting T cell mediated killing. To activate anti-tumor immunity, we targeted tumor cell - natural killer (NK) cell interactions.
View Article and Find Full Text PDFMICB*002:06, a novel exonic variant of MICB (MHC class I chain-related gene B).
HLA
August 2024
Shenzhen Blood Center, Shenzhen Institute of Transfusion Medicine, Shenzhen, Guangdong, China.
MICB*002:06 differs from MICB*002:01:01 by one nucleotide change at nucleotide 33 in exon 1 from C to T.
View Article and Find Full Text PDFCharacterisation of novel MICB alleles by next generation sequencing: MICB*055 and MICB*005:15.
HLA
June 2024
Department of Clinical Immunology, Alexandrovska University Hospital, Medical University Sofia, Sofia, Bulgaria.
Two novel MICB alleles with coding polymorphisms in exon 3 were detected by next generation sequencing.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!